Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial

被引：3
|
作者：
Navari, Rudolph M.
Qin, Rui
Ruddy, Kathryn Jean
Liu, Heshan
Powell, Steven Francis
Bajaj, Madhuri
Dietrich, Leah L.
Lafky, Jacqueline M.
Loprinzi, Charles L.
机构：
[1] Indiana Univ Sch Med South Bend, Mishawaka, IN USA
[2] Mayo Clin, Alliance Stat & Data Ctr, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Sanford Hlth, Sioux Falls, SD USA
[5] Illinois Canc Care, Peoria, IL USA
[6] Gundersen Hlth Syst, La Crosse, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 29期
关键词：
D O I：
10.1200/jco.2015.33.29_suppl.176
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
176
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study
    Mizukami, Naomi
    Yamauchi, Masanori
    Koike, Kazuhiko
    Watanabe, Akihiko
    Ichihara, Koji
    Masumori, Naoya
    Yamakage, Michiaki
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2014, 47 (03) : 542 - 550
  • [2] A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Jeon, So Yeon
    Han, Hye Sook
    Bae, Woo Kyun
    Park, Moo-Rim
    Lee, Sang-Cheol
    Go, Se-Ii
    Yun, Hwan Jung
    Ryu, Hyewon
    Im, Yong-Jin
    Song, Eun-Kee
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Sugawara, Shunichi
    Inui, Naoki
    Kanehara, Masashi
    Morise, Masahiro
    Yoshimori, Kozo
    Kumagai, Toru
    Fukui, Tomoya
    Minato, Koichi
    Iwashima, Akira
    Takeda, Yuichiro
    Kubota, Kaoru
    Saeki, Toshiaki
    Tamura, Tomohide
    CANCER, 2019, 125 (22) : 4076 - 4083
  • [4] Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)
    Navari, Rudolph M.
    Le-Rademacher, Jennifer
    Smieliauskas, Fabrice
    Ruddy, Kathryn J.
    James Saphner, Thomas
    Liu, Heshan
    Harlos, Elizabeth
    Onitilo, Adedayo A.
    Giridhar, Karthik
    Paul Singh, Preet
    Reddy, Pavan S.
    Chow, Selina
    Kruter, Flavio
    Raptis, George
    Loprinzi, Charles L.
    ONCOLOGIST, 2023, : 722 - 729
  • [5] Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
    Navari, Rudolph M.
    Le-Rademacher, Jennifer
    Smieliauskas, Fabrice
    Ruddy, Kathryn Jean
    Saphner, Thomas James
    Liu, Heshan
    Harlos, Beth
    Onitilo, Adedayo A.
    Giridhar, Karthik
    Singh, Preet Paul
    Reddy, Pavan S.
    Kruter, Flavio
    Raptis, George
    Loprinzi, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy
    Suthinee Ithimakin
    Pathra Theeratrakul
    Apirom Laocharoenkiat
    Akarin Nimmannit
    Charuwan Akewanlop
    Nopadol Soparattanapaisarn
    Sirisopa Techawattanawanna
    Krittiya Korphaisarn
    Pongwut Danchaivijitr
    Supportive Care in Cancer, 2020, 28 : 5335 - 5342
  • [7] Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy
    Ithimakin, Suthinee
    Theeratrakul, Pathra
    Laocharoenkiat, Apirom
    Nimmannit, Akarin
    Akewanlop, Charuwan
    Soparattanapaisarn, Nopadol
    Techawattanawanna, Sirisopa
    Korphaisarn, Krittiya
    Danchaivijitr, Pongwut
    SUPPORTIVE CARE IN CANCER, 2020, 28 (11) : 5335 - 5342
  • [8] LIKELIHOOD OF A SUBSEQUENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) EVENT IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)
    Feinberg, B.
    Gilmore, J.
    Haislip, S.
    Jackson, J.
    Jain, G.
    Balu, S.
    Buchner, D.
    VALUE IN HEALTH, 2010, 13 (07) : A251 - A251
  • [9] Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
    Gao, Ai
    Guan, Shasha
    Sun, Yinjuan
    Wang, Lingling
    Meng, Fanlu
    Liu, Xia
    Gu, Liyan
    Li, Guo
    Zhong, Diansheng
    Zhang, Linlin
    BMC CANCER, 2023, 23 (01)
  • [10] Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
    Ai Gao
    Shasha Guan
    Yinjuan Sun
    Lingling Wang
    Fanlu Meng
    Xia Liu
    Liyan Gu
    Guo Li
    Diansheng Zhong
    Linlin Zhang
    BMC Cancer, 23
12345